Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

If Eli Lilly has its way ... Back then, the once-weekly drug was only approved to treat type 2 diabetes. It took a while to become popular as an off-label weight loss aid. Once it did, demand ...

Jan 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab obesity ... Zepbound and Lilly's other blockbuster diabetes drug, Mounjaro, belong to a class of drugs called GLP-1 agonists.

Eli Lilly (LLY) shares traded down more than 6 ... Mounjaro and Zepbound — to miss consensus as well. Guidance for diabetes drug Mounjaro is $3.5 billion, while weight loss drug Zepbound is ...

GLP-1 drugs still lead the way for Eli Lilly Turning to its GLP-1 drugs ... help improve blood glucose levels in adults with type 2 diabetes, but is commonly used off-label for weight loss.

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

Eli Lilly's obesity drug Zepbound can now be covered ... Zepbound and Lilly's other blockbuster diabetes drug, Mounjaro, belong to a class of drugs called GLP-1 agonists. Analysts have forecast ...

Eli Lilly’s (LLY) shares slumped over 8% on Tuesday after the company projected fourth-quarter sales of its weight-loss drug Zepbound and diabetes treatment Mounjaro to fall short of Wall Street ...